Our dedicated HTA team are true experts when it comes to devising the optimal strategy for your technology, generating a robust HTA-ready evidence package, and delivering the highest quality HTA submission dossiers.

As part of their transformation plan, the UK National Institute for Health and Care Excellence (NICE) are introducing important changes to their methods and processes to focus on relevance, timeliness, usability and impact, in order to meet the pressures of a rapidly changing health and care system and an ever-increasing demand for their products. Our HTA team were delighted to participate in public consultations on these changes in March 2024, and have summarised our key takeaways on integrated topic prioritisation and the inclusion of technology appraisal guidance in NICE guidelines and their implications for UK health technology assessment (HTA).

We help to place your technology in the strongest position to withstand scrutiny from any HTA body and optimise the likelihood of a positive recommendation for reimbursement.

We deliver a fully comprehensive HTA evidence package that places your technology in the strongest position to withstand scrutiny from any HTA body and optimises the likelihood of a positive recommendation for reimbursement. Our service offerings cover early gap analyses and scientific advice, the generation of HTA-standard literature reviews, statistical analysis and real-world evidence, and ultimately the development of the highest quality HTA submission dossiers and associated health economic models.

Our website uses cookies to distinguish you from other users. This helps us to provide you with a good experience when you browse our website and also allows us to improve our site. Cookies are files saved on your phone, tablet or computer generated when you visit a website and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful. The cookies collect information in a way that does not directly identify you. For full details, please see our Privacy Policy.

We use a set of third party tools to provide information of how our users engage with our website so that we can improve the experience of the website for our users. For example, we collect information about which of our pages are most frequently visited, and by which types of users. We also use third-party cookies to help with performance.

© 2024 Costello Medical Consulting Limited VAT Number: 942 1421 53. Company Number: 06746770. Registered in England and Wales. Costello Medical® is a registered trade mark of Costello Medical Consulting Limited

Our HTA service offerings span early HTA planning and strategy, the generation of HTA-standard literature reviews, statistical analysis and real-world evidence, and the development of the highest quality HTA submission dossiers and associated health economic models.

We have a dedicated Rare Diseases team who specialise in the delivery of HTA evidence generation and submission dossier delivery in the rare diseases space. We also provide guidance on engaging with patients/patient organisations throughout the appraisal process. Beyond pharmaceuticals, we have experience in the delivery of early HTA planning and strategy, HTA evidence generation, economic modelling and HTA submission dossier writing for devices and diagnostics, in collaboration with our MedTech team.

We work as one internal team to deliver all components of your HTA evidence package. We firmly believe that in doing so we can offer a solution that is not only more efficient, but that also results in a strong, consistent and self-reinforcing HTA narrative throughout the HTA submission dossier.

To date, we have supported the development of over 260 health technology assessment (HTA) submission dossiers, including over 110 submission dossiers to NICE, and over 150 submission dossiers across Europe (Scotland, Wales, Ireland, Sweden, Greece, Belgium, Spain), North America (CADTH, AMCP) and the APAC region (Singapore).

Please note that we will not be able to process your online account unless you currently have a trade account set up with us.

We are experienced in advising clients on wide-ranging strategic HTA challenges, such as immature survival data and uncertainty in long-term clinical effectiveness, lack of data for relevant comparators and the use of real-world evidence, difficulties in demonstrating cost-effectiveness at the desired price, and the use of the most appropriate methods for indirect treatment comparison.

We have also reflected on our experience developing over 10 appraisals under NICE’s proportionate approach to technology appraisal (PATT), highlighting the key challenges and opportunities we have encountered so far – we participated in the public consultation on the PATT in summer 2023, which informed the first modular update to the NICE manual for health technology evaluation in October 2023.

We are true experts when it comes to devising the optimal strategy for your technology, generating a robust HTA-ready evidence package, and delivering the highest quality HTA submission dossiers.

We genuinely care about the outcome of our clients’ HTA submissions as much as they do. We aim to become an integral part of the client team, providing technical expertise and the highest quality deliverables to form the complete HTA evidence package alongside proactive and responsible project management support.

Costello Medical would like to set Google Analytics cookies to collect information on how you use our website to help us to improve it. The cookies collect information in a way that does not directly identify you. For more information, please see our Privacy Policy.

Guest account doesn't allow you to see the prices or place orders. If you already have an Online Login please sign in.

Our extensive experience in writing for HTA, coupled with thorough postgraduate-level training in health economics received by most of our medical writers, makes us ideally placed to seamlessly weave together the clinical and economic stories within your HTA submission dossier, and develop a clear, evidence-based and persuasive narrative.

We are keen contributors of research on key advances in HTA methods and processes at international conferences, including posters, oral presentations, workshops, and issue panels presented at ISPOR and HTAi. Explore our dedicated pages to find out more.